CN1117089C - 取代的2－(2,6－二氧哌啶－3－基)－邻苯二甲酰亚胺和－1－氧异二氢吲哚及降低肿瘤坏死因子α的方法 - Google Patents

取代的2－(2,6－二氧哌啶－3－基)－邻苯二甲酰亚胺和－1－氧异二氢吲哚及降低肿瘤坏死因子α的方法 Download PDF

Info

Publication number
CN1117089C
CN1117089C CN97180299A CN97180299A CN1117089C CN 1117089 C CN1117089 C CN 1117089C CN 97180299 A CN97180299 A CN 97180299A CN 97180299 A CN97180299 A CN 97180299A CN 1117089 C CN1117089 C CN 1117089C
Authority
CN
China
Prior art keywords
oxo
dioxopiperidin
hydrogen
compound
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
CN97180299A
Other languages
English (en)
Chinese (zh)
Other versions
CN1239959A (zh
Inventor
G·W·马勒
D·I·斯特林
R·Sc·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27367302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1117089(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08690258 external-priority patent/US5635517B1/en
Priority claimed from US08/701,494 external-priority patent/US5798368A/en
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CN1239959A publication Critical patent/CN1239959A/zh
Application granted granted Critical
Publication of CN1117089C publication Critical patent/CN1117089C/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN97180299A 1996-07-24 1997-07-24 取代的2－(2,6－二氧哌啶－3－基)－邻苯二甲酰亚胺和－1－氧异二氢吲哚及降低肿瘤坏死因子α的方法 Ceased CN1117089C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/690,258 1996-07-24
US08690258 US5635517B1 (en) 1996-07-24 1996-07-24 Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US08/701,494 US5798368A (en) 1996-08-22 1996-08-22 Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US08/701,494 1996-08-22
US4827897P 1997-05-30 1997-05-30
US60/048,278 1997-05-30

Publications (2)

Publication Number Publication Date
CN1239959A CN1239959A (zh) 1999-12-29
CN1117089C true CN1117089C (zh) 2003-08-06

Family

ID=27367302

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97180299A Ceased CN1117089C (zh) 1996-07-24 1997-07-24 取代的2－(2,6－二氧哌啶－3－基)－邻苯二甲酰亚胺和－1－氧异二氢吲哚及降低肿瘤坏死因子α的方法

Country Status (21)

Country Link
EP (4) EP0925294B3 (enExample)
JP (1) JP4065567B2 (enExample)
KR (2) KR20050032629A (enExample)
CN (1) CN1117089C (enExample)
AT (4) ATE530542T1 (enExample)
CA (3) CA2624949C (enExample)
CZ (3) CZ304569B6 (enExample)
DE (4) DE69717831T3 (enExample)
DK (2) DK0925294T6 (enExample)
ES (4) ES2187805T7 (enExample)
FI (1) FI120687B (enExample)
FR (1) FR07C0056I2 (enExample)
HU (1) HUS1300056I1 (enExample)
LU (1) LU91359I2 (enExample)
NL (1) NL300291I2 (enExample)
NZ (1) NZ333903A (enExample)
PL (2) PL195916B1 (enExample)
PT (4) PT2177517E (enExample)
SK (1) SK9199A3 (enExample)
UA (1) UA60308C2 (enExample)
WO (1) WO1998003502A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101620B2 (en) 2009-11-02 2015-08-11 Nanjing Cavendish Bio-Engineering Technology Co., Ltd. Polymorph of 3-(substituteddihydroisoindolinone-2-yl)-2,6-dioxopiperidine, and pharmaceutical compositions thereof
CN105440013A (zh) * 2014-08-29 2016-03-30 杭州和泽医药科技有限公司 一种泊马度胺的制备方法

Families Citing this family (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
PL195916B1 (pl) * 1996-07-24 2007-11-30 Celgene Corp Izomery optyczne podstawionej 1-okso-izoindoliny i 1,3-diokso-izoindoliny, kompozycje farmaceutyczne je zawierające oraz ich zastosowanie
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
DE19703763C1 (de) * 1997-02-01 1998-10-01 Gruenenthal Gmbh Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione
CZ299808B6 (cs) * 1997-11-18 2008-12-03 Celgene Corporation Substituované 2-(2,6-dioxo-3-fluoropiperidin-3-yl)izoindoliny a jejich použití za úcelem snížení hladin TNFalfa
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
JP4695259B2 (ja) * 1998-03-16 2011-06-08 セルジーン コーポレイション ２−（２，６−ジオキソピペリジン−３−イル）イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用
AU771015B2 (en) 1999-03-18 2004-03-11 Celgene Corporation Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
DE19917195B4 (de) * 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
JP4242651B2 (ja) * 2000-11-30 2009-03-25 ザ チルドレンズ メディカル センター コーポレイション ４−アミノ−サリドマイドエナンチオマーの合成法
CN1487935A (zh) * 2000-12-11 2004-04-07 ����ҩƷ��ҵ��ʽ���� 改良型水溶性药物组合物
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
ES2338534T3 (es) * 2001-02-27 2010-05-10 The Governement Of The Usa, Represented By The Secretary Department Of Health And Human Services Analogos de talidomina como inhibidores de la angiogenesis.
ES2325916T3 (es) * 2001-08-06 2009-09-24 The Children's Medical Center Corporation Actividad antiangiogenica de analogos de talidomida sustituidos con nitrogeno.
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
CA2752140A1 (en) 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
US8404717B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
EP1900369A1 (en) 2002-10-15 2008-03-19 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
FR2845994B1 (fr) * 2002-10-18 2006-05-19 Servier Lab Nouveaux derives de benzo[e][1,4]oxazino[3,2-g]isoindole substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN1326522C (zh) * 2002-10-24 2007-07-18 细胞基因公司 用于治疗、改变和控制疼痛的包含免疫调节化合物的组合物
NZ540186A (en) * 2002-10-31 2008-03-28 Celgene Corp Composition for the treatment of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CH696542A5 (de) * 2003-07-09 2007-07-31 Siegfried Ltd Verfahren zur Herstellung von substituierten 2,6-Dioxopiperidin-3-yl-Verbindungen.
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7973057B2 (en) 2003-09-17 2011-07-05 The United States Of America As Represented By The Department Of Health And Human Services Thalidomide analogs
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
US7612096B2 (en) 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
KR101224262B1 (ko) 2004-03-22 2013-01-21 셀진 코포레이션 면역조절 화합물을 포함하는 피부 질환 또는 장애의 치료및 관리용 조성물 및 이의 사용 방법
CN1984657B (zh) * 2004-05-05 2010-12-15 细胞基因公司 用于治疗和控制骨髓增生性疾病的包含免疫调节化合物的组合物和使用方法
EP2479172B1 (en) 2004-09-03 2013-10-09 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
CA2612612C (en) 2005-06-30 2014-03-11 Celgene Corporation Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
US7928280B2 (en) 2005-07-13 2011-04-19 Anthrogenesis Corporation Treatment of leg ulcers using placenta derived collagen biofabric
BRPI0614995A2 (pt) 2005-08-31 2010-01-12 Celgene Corp composto ou um sal, solvato ou estereoisemero farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de uma quantidade terapêutica ou profilaticamente eficaz de um composto ou um sal, solvato ou estereoisemero farmaceuticamente aceitável do mesmo, e, forma de dosagem unitária única
EP1928492B1 (en) 2005-09-01 2011-02-23 Celgene Corporation Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy
US20070066512A1 (en) 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物
CA2633980A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
WO2007106884A2 (en) 2006-03-15 2007-09-20 Theralogics, Inc. Methods of treating muscular wasting diseases using nf-kb activation inhibitors
WO2007136640A2 (en) * 2006-05-16 2007-11-29 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
CL2007002218A1 (es) 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
US8105634B2 (en) 2006-08-15 2012-01-31 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
CL2007002513A1 (es) * 2006-08-30 2008-04-04 Celgene Corp Soc Organizada Ba Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
CN102898416A (zh) 2006-09-26 2013-01-30 细胞基因公司 作为抗肿瘤剂的5-取代的喹唑酮衍生物
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
WO2008060377A2 (en) 2006-10-04 2008-05-22 Anthrogenesis Corporation Placental or umbilical cord tissue compositions
EP2076279B1 (en) 2006-10-06 2014-08-27 Anthrogenesis Corporation Native (telopeptide) placental collagen compositions
KR101593242B1 (ko) 2007-09-26 2016-02-11 셀진 코포레이션 ６-, ７- 또는 ８-치환된 퀴나졸리논 유도체, 및 그를 포함하는 조성물 및 그의 사용 방법
AU2008307633C1 (en) 2007-09-28 2015-04-30 Celularity Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
US20090088393A1 (en) * 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
CN101909609A (zh) * 2007-11-08 2010-12-08 细胞基因公司 免疫调节化合物在治疗与内皮功能障碍有关的紊乱中的用途
WO2009085234A2 (en) 2007-12-20 2009-07-09 Signal Pharmaceuticals, Inc. Use of micro-rna as a biomarker of immunomodulatory drug activity
AU2009223014A1 (en) * 2008-03-11 2009-09-17 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
WO2009111948A1 (zh) * 2008-03-13 2009-09-17 天津和美生物技术有限公司 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用
US20110060010A1 (en) * 2008-03-13 2011-03-10 Tianjin Hemay Bio-Tech Co., Ltd Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
PE20140963A1 (es) 2008-10-29 2014-08-06 Celgene Corp Compuestos de isoindolina para el tratamiento de cancer
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
MX2011005112A (es) * 2008-11-14 2011-06-16 Concert Pharmaceuticals Inc Derivados de dioxopiperidinil-ftalimida sustituida.
DE102008057335A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh Amorphes Lenalidomid
DE102008057284A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
DE102008057285A1 (de) 2008-11-14 2010-05-20 Ratiopharm Gmbh 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidindion in Form einer festen Lösung
EP2396312A1 (en) 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of lenalidomide
ES2713524T3 (es) 2009-03-25 2019-05-22 Celularity Inc Supresión tumoral usando linfocitos citolíticos naturales intermedios obtenidos a partir de placenta humana y compuestos inmunomoduladores
DK2391355T3 (en) 2009-05-19 2017-02-27 Celgene Corp FORMULATIONS OF 4-AMINO-2- (2,6-DIOXOPIPERIDIN-3-YL) ISOINDOLIN-1,3-DION
US20120134969A1 (en) 2009-05-25 2012-05-31 Hiroshi Handa Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells
CN101580501B (zh) 2009-06-01 2011-03-09 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
US20120184746A1 (en) 2009-09-03 2012-07-19 Ranbaxy Laboratories Limited Process for the preparation of lenalidomide
WO2011050962A1 (en) 2009-10-29 2011-05-05 Ratiopharm Gmbh Acid addition salts of lenalidomide
CN102127054B (zh) * 2009-11-02 2013-04-03 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
WO2011069608A1 (en) 2009-12-09 2011-06-16 Ratiopharm Gmbh S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide
BR112012015129A2 (pt) 2009-12-22 2019-09-24 Celgene Corp "composto, composição farmacêutica e método para tratar, controlar ou prevenir uma doença ou distúrbio"
EP2521543B1 (en) 2010-01-05 2016-04-13 Celgene Corporation A combination of an immunomodulatory compound and an artemisinin derivative for treating cancer
SG10201501062SA (en) 2010-02-11 2015-04-29 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
US9408831B2 (en) 2010-04-07 2016-08-09 Celgene Corporation Methods for treating respiratory viral infection
WO2012078492A1 (en) 2010-12-06 2012-06-14 Celgene Corporation A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
CN103402980B (zh) 2011-01-10 2016-06-29 细胞基因公司 作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物
EA026100B1 (ru) 2011-03-11 2017-03-31 Селджин Корпорейшн Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение
AU2012236655B2 (en) 2011-03-28 2016-09-22 Deuterx, Llc, 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
MX2013012083A (es) 2011-04-18 2014-04-16 Celgene Corp Biomarcadores para el tratamiento de mieloma multiple.
CN103688176A (zh) 2011-04-29 2014-03-26 细胞基因公司 利用cereblon作为预报因子治疗癌和炎性疾病的方法
US20140221427A1 (en) 2011-06-22 2014-08-07 Celgene Corporation Isotopologues of pomalidomide
PH12014500593A1 (en) 2011-09-14 2019-09-02 Celgene Corp Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
SG10201605251VA (en) 2011-12-27 2016-08-30 Celgene Corp Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione
ES2671608T3 (es) * 2012-02-21 2018-06-07 Celgene Corporation Formas sólidas de 3-(4-nitro-1-oxoisoindolin-2-il)piperidina-2,6-diona
WO2013182662A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Vaccine
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
PE20150617A1 (es) 2012-08-09 2015-05-21 Celgene Corp Formas solidas de 3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona o un estereoisomero del mismo, de sus sales, y composiciones que comprenden las mismas
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
WO2014066243A1 (en) 2012-10-22 2014-05-01 Concert Pharmaceuticals, Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
FR2999914B1 (fr) * 2012-12-21 2015-08-07 Oreal Utilisation de derives de l'acide imidocarboxylique pour traiter les alterations de la peau liees a l'age ou au photovieillissement
FR2999915B1 (fr) * 2012-12-21 2017-08-11 Oreal Utilisation de derives de l'acide imidocarboxylique en tant qu'agent apaisant
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
CA2935495C (en) 2013-01-14 2021-04-20 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014123879A1 (en) 2013-02-05 2014-08-14 Anthrogenesis Corporation Natural killer cells from placenta
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
CN105518018B (zh) 2013-03-15 2020-04-03 细胞基因公司 修饰的t淋巴细胞
CN104072476B (zh) * 2013-03-27 2018-08-21 江苏豪森药业集团有限公司 泊马度胺晶型及其制备方法和用途
TW201526897A (zh) 2013-04-17 2015-07-16 Signal Pharm Llc 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
CN103497174B (zh) * 2013-07-29 2015-10-28 杭州派臣医药科技有限公司 泊利度胺的制备和精制方法
CN107188884A (zh) * 2013-10-29 2017-09-22 上海医药工业研究院 一种泊利度胺的纯化方法
CN104557858B (zh) * 2013-10-29 2018-06-01 上海医药工业研究院 一种泊利度胺的制备方法
CN105939716A (zh) 2013-12-03 2016-09-14 埃斯泰隆制药公司 组蛋白脱乙酰基酶抑制剂和免疫调节药物的组合
CN104016967A (zh) * 2014-04-04 2014-09-03 南京工业大学 一种泊利度胺的合成方法
KR20250127179A (ko) * 2014-04-14 2025-08-26 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
JP6640126B2 (ja) 2014-06-27 2020-02-05 セルジーン コーポレイション セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法
CN105348257A (zh) * 2014-08-20 2016-02-24 河北菲尼斯生物技术有限公司 泊马度胺的制备方法
LT3182996T (lt) 2014-08-22 2023-03-10 Celgene Corporation Daugybinės mielomos gydymo būdai imunomoduliuojančiais junginiais derinyje su antikūnais
ES2812877T3 (es) * 2014-10-30 2021-03-18 Kangpu Biopharmaceuticals Ltd Derivado de isoindolina, producto intermedio, método de preparación, composición farmacéutica y uso del mismo
WO2016097030A1 (en) 2014-12-19 2016-06-23 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide
US10471156B2 (en) 2014-12-19 2019-11-12 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide
CN104447689B (zh) * 2014-12-22 2016-07-20 上海迈柏医药科技有限公司 来那度胺的晶型及其制备方法
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11352351B2 (en) 2015-01-20 2022-06-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
RU2694895C2 (ru) * 2015-05-22 2019-07-18 Биотерикс, Инк. Нацеленные на белки соединения, их композиции, способы и применения
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
EP3313818B1 (en) 2015-06-26 2023-11-08 Celgene Corporation Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
AU2016378482A1 (en) 2015-12-22 2018-07-12 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
WO2017201069A1 (en) 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
HUE070289T2 (hu) 2016-10-11 2025-05-28 Arvinas Operations Inc Vegyületek és módszerek az androgénreceptor célzott lebontására
KR20230127371A (ko) 2016-11-01 2023-08-31 아비나스 오퍼레이션스, 인코포레이티드 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
IL297717A (en) 2016-12-01 2022-12-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
MA46961A (fr) 2016-12-03 2019-10-09 Juno Therapeutics Inc Procédés de modulation de lymphocytes t modifiés par car
KR102368555B1 (ko) 2016-12-16 2022-02-28 강푸 바이오파마슈티칼즈 리미티드 조성물, 이의 적용 및 치료 방법
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
MX2019007649A (es) 2016-12-23 2019-09-10 Arvinas Operations Inc Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente.
WO2018119441A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Egfr proteolysis targeting chimeric molecules and associated methods of use
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
IL300417A (en) 2017-01-26 2023-04-01 Arvinas Operations Inc Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
EP3577109A4 (en) 2017-01-31 2020-11-18 Arvinas Operations, Inc. CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM
US20200000776A1 (en) 2017-02-13 2020-01-02 Kangpu Biopharmaceuticals, Ltd. Combination treating prostate cancer, pharmaceutical composition and treatment method
CA3061945A1 (en) 2017-05-01 2018-11-08 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
US10093647B1 (en) 2017-05-26 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
KR20200054160A (ko) 2017-06-02 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
AU2018291032A1 (en) 2017-06-29 2020-01-16 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
TWI793151B (zh) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
US10093648B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
US10093649B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
CA3077325A1 (en) 2017-09-28 2019-04-04 Celularity Inc. Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
CA3080904A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
WO2019118937A1 (en) 2017-12-15 2019-06-20 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
EP3505158A1 (en) 2017-12-27 2019-07-03 KRKA, d.d., Novo mesto Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt
US11452722B2 (en) 2018-01-11 2022-09-27 Natco Pharma Limited Stable pharmaceutical compositions comprising lenalidomide
EP3743066A4 (en) 2018-01-26 2021-09-08 Yale University IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE
MX2020008718A (es) 2018-02-21 2020-12-07 Celgene Corp Anticuerpos de union a bcma y usos de los mismos.
EP3545949A1 (en) 2018-03-29 2019-10-02 Midas Pharma GmbH Oral dosage forms comprising pomalidomide crystalline form a
JP7720698B2 (ja) 2018-04-04 2025-08-08 アルビナス・オペレーションズ・インコーポレイテッド タンパク質分解の調節因子および関連する使用方法
KR102286499B1 (ko) 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 약제학적 조성물
KR102259798B1 (ko) 2018-04-13 2021-06-02 주식회사 삼양홀딩스 붕해가 개선된 레날리도마이드의 경구용 정제 조성물
KR102286500B1 (ko) 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
KR102286498B1 (ko) 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드의 경구용 코팅 정제 조성물
JP2021518424A (ja) 2018-04-13 2021-08-02 サムヤン バイオファーマシューティカルズ コーポレイションＳａｍｙａｎｇ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 様々な用量のレナリドミドの経口用錠剤組成物
CN112912376A (zh) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
MX2021005366A (es) 2018-11-08 2021-09-10 Juno Therapeutics Inc Metodos y combinaciones para el tratamiento y modulacion de celulas t.
CA3120118A1 (en) 2018-11-16 2020-05-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
WO2020113194A2 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
EP3891128A4 (en) * 2018-12-05 2022-08-17 Vividion Therapeutics, Inc. SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEOSUBSTRATE RECRUITMENT
MX2021009087A (es) 2019-01-29 2021-09-08 Juno Therapeutics Inc Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1).
US20230248696A1 (en) * 2019-05-03 2023-08-10 Dynamic Biologics Inc. Lenalidomide prodrugs, polymeric conjugates, and formulations thereof, and their uses for the treatment of multiple myeloma
CN110343063A (zh) * 2019-08-09 2019-10-18 新乡双鹭药业有限公司 一种泊马度胺合成中杂质的制备方法
EP4021450B1 (en) 2019-08-26 2025-11-05 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
US11535606B2 (en) 2019-09-23 2022-12-27 Accutar Biotechnology Inc. Substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof
CN114761003B (zh) * 2019-09-23 2023-12-29 冰洲石生物科技公司 具有雄激素受体降解活性的新型脲类及其用途
AU2020368542B2 (en) 2019-10-17 2024-02-29 Arvinas Operations, Inc. Bifunctional molecules containing an E3 ubiquitine ligase binding moiety linked to a BCL6 targeting moiety
IL293027A (en) 2019-11-19 2022-07-01 Bristol Myers Squibb Co Compounds useful as inhibitors of Helios protein
EP4076464A4 (en) * 2019-12-17 2024-06-12 Orionis Biosciences, Inc. COMPOUNDS FOR MODULATION OF PROTEIN RECRUITMENT AND/OR DEGRADATION
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
BR112022020897A2 (pt) 2020-04-15 2022-11-29 Tecnimede Sociedade Tecnico Medicinal Sa Forma de dosagem oral sólida compreendendo pomalidomida.
MX2022014071A (es) 2020-05-09 2023-01-30 Arvinas Operations Inc Metodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificacion que comprenden el mismo.
EP4204418A1 (en) 2020-08-28 2023-07-05 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
EP4211128A1 (en) 2020-09-14 2023-07-19 Arvinas Operations, Inc. Crystalline forms of a compound for the targeted degradation of estrogen receptor
WO2022152821A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
RS66982B1 (sr) 2021-04-06 2025-07-31 Bristol Myers Squibb Co Piridinil supstituisana oksoizoindolinska jedinjenja
EP4323352A1 (en) 2021-04-16 2024-02-21 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use
WO2023126530A1 (en) 2021-12-31 2023-07-06 A Fine House S.A. Oral solution comprising lenalidomide
EP4456876A1 (en) 2021-12-31 2024-11-06 a Fine House S.A. Lenalidomide oral solution
JP2025521543A (ja) 2022-06-22 2025-07-10 ジュノー セラピューティクス インコーポレイテッド Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法
TW202432544A (zh) 2022-09-07 2024-08-16 美商亞文納營運公司 快速加速纖維肉瘤降解化合物及相關使用方法
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
TW202444727A (zh) 2023-01-26 2024-11-16 美商艾維納斯手術有限公司 基於cereblon之kras降解protac及其相關用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
WO1992014455A1 (en) * 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
DE4422237A1 (de) * 1994-06-24 1996-01-04 Gruenenthal Gmbh Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe
PL195916B1 (pl) * 1996-07-24 2007-11-30 Celgene Corp Izomery optyczne podstawionej 1-okso-izoindoliny i 1,3-diokso-izoindoliny, kompozycje farmaceutyczne je zawierające oraz ich zastosowanie
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101620B2 (en) 2009-11-02 2015-08-11 Nanjing Cavendish Bio-Engineering Technology Co., Ltd. Polymorph of 3-(substituteddihydroisoindolinone-2-yl)-2,6-dioxopiperidine, and pharmaceutical compositions thereof
CN105440013A (zh) * 2014-08-29 2016-03-30 杭州和泽医药科技有限公司 一种泊马度胺的制备方法

Also Published As

Publication number Publication date
EP0925294B3 (en) 2018-07-04
AU3899897A (en) 1998-02-10
DE69717831T2 (de) 2003-08-28
ES2529190T3 (es) 2015-02-17
JP2001503384A (ja) 2001-03-13
PL191566B1 (pl) 2006-06-30
EP0925294A1 (en) 1999-06-30
FI120687B (fi) 2010-01-29
EP1285916A1 (en) 2003-02-26
HK1143360A1 (en) 2010-12-31
KR20050032629A (ko) 2005-04-07
HK1021819A1 (en) 2000-07-07
ATE460409T1 (de) 2010-03-15
FR07C0056I1 (enExample) 2007-12-14
PL195916B1 (pl) 2007-11-30
PT2177517E (pt) 2011-11-10
NZ333903A (en) 2000-02-28
CZ302378B6 (cs) 2011-04-20
DE69717831C5 (de) 2008-03-20
PL332867A1 (en) 1999-10-25
CA2261762C (en) 2008-06-17
CA2624949C (en) 2011-02-15
NL300291I1 (nl) 2007-11-01
AU715779B2 (en) 2000-02-10
CZ304569B6 (cs) 2014-07-09
EP2070920B1 (en) 2011-03-02
DE69739802D1 (de) 2010-04-22
ES2187805T7 (es) 2018-08-17
DE69717831D1 (de) 2003-01-23
FI990101L (fi) 1999-03-19
LU91359I2 (fr) 2007-11-06
ES2187805T3 (es) 2003-06-16
PT925294E (pt) 2003-04-30
DK0925294T6 (da) 2018-08-20
ES2339425T3 (es) 2010-05-20
CA2624949A1 (en) 1998-01-29
ATE229521T3 (de) 2002-12-15
CZ20299A3 (cs) 1999-06-16
EP2070920A1 (en) 2009-06-17
UA60308C2 (uk) 2003-10-15
NL300291I2 (nl) 2008-03-03
DE69717831T3 (de) 2018-08-30
DE122007000079I1 (de) 2008-02-28
DE122007000079I2 (de) 2010-08-12
CA2560523A1 (en) 1998-01-29
JP4065567B2 (ja) 2008-03-26
KR100534498B1 (ko) 2005-12-08
EP0925294B1 (en) 2002-12-11
HK1050893A1 (en) 2003-07-11
EP2070920B8 (en) 2011-04-27
PT1285916E (pt) 2010-04-05
SK9199A3 (en) 1999-07-12
ES2372577T3 (es) 2012-01-24
LU91359I9 (enExample) 2018-12-31
EP2305663B1 (en) 2014-12-17
HK1132502A1 (en) 2010-02-26
FR07C0056I2 (enExample) 2008-05-09
CA2261762A1 (en) 1998-01-29
CA2560523C (en) 2011-09-20
KR20000068008A (ko) 2000-11-25
CN1239959A (zh) 1999-12-29
ATE530542T1 (de) 2011-11-15
DE69740140D1 (de) 2011-04-14
HK1153736A1 (en) 2012-04-05
DK1285916T3 (da) 2010-04-26
CZ295762B6 (cs) 2005-10-12
PT2070920E (pt) 2011-03-31
DK0925294T3 (da) 2003-04-07
ATE500240T1 (de) 2011-03-15
EP1285916B1 (en) 2010-03-10
WO1998003502A1 (en) 1998-01-29
HUS1300056I1 (hu) 2016-08-29
EP2305663A1 (en) 2011-04-06
FI990101A0 (fi) 1999-01-19

Similar Documents

Publication Publication Date Title
CN1117089C (zh) 取代的2－(2,6－二氧哌啶－3－基)－邻苯二甲酰亚胺和－1－氧异二氢吲哚及降低肿瘤坏死因子α的方法
CN1265590A (zh) 取代的链烷异羟肟酸及降低肿瘤坏死因子α水平的方法
CN1271067C (zh) 取代的2－(2,6－二氧－3－氟哌啶－3－基)－异二氢吲哚及其降低肿瘤坏死因子α水平的用途
CN1277828C (zh) 哌嗪衍生物
CN1193025C (zh) 新的1,3－二氢－2h－吲哚－2－酮衍生物,它们的制备方法以及含有它们的药物组合物
CN1179945C (zh) 吲哚衍生物、其制备方法及用途
CN1024547C (zh) 一类环胺化合物的制备方法
CN1420889A (zh) 具有药物活性的二氢异吲哚衍生物
CN1254333A (zh) 新的免疫治疗剂亚酰胺/酰胺类
CN1161333C (zh) 作为生长激素释放剂的2-羟基吲哚衍生物
CN1911927A (zh) 取代的2－(2,6－二氧哌啶－3－基)－邻苯二甲酰亚胺和－1－氧异二氢吲哚及降低肿瘤坏死因子α水平的方法
CN1784382A (zh) 7－氨基－异吲哚基化合物及其药物用途
CN1575174A (zh) 有药学活性的异吲哚啉衍生物
CN1413109A (zh) 取代的酰基异羟肟酸和降低TNF－α水平的方法
CN1413211A (zh) 取代的1,3,4－氧二氮茂及降低TNF－α水平的方法
CN1261880A (zh) 法尼基蛋白转移酶的抑制剂
CN1549814A (zh) 作为1型纤溶酶原激活物抑制剂(pai-1)的抑制剂的取代萘基吲哚衍生物
CN1474809A (zh) 氰基吡咯烷衍生物
CN1062730A (zh) N-酰基-2，3-苯并环二氮己三烯衍生物及其药物组合物和制备方法
CN1500081A (zh) 乙内酰硫脲及其在治疗糖尿病方面的用途
CN1795174A (zh) 新型取代的3－硫吲哚
CN1665502A (zh) Mchir拮抗剂
CN1072219C (zh) 二氮杂䓬酮、其生产和用途
CN1659164A (zh) 苯并噁嗪酮衍生的化合物、它们的制备方法和作为药物的用途
CN1250542C (zh) 具有抗肿瘤活性的2－(1h－吲哚－3－基)－2－氧代－乙酰胺

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C35 Partial or whole invalidation of patent or utility model
IP01 Partial invalidation of patent right

Commission number: 4W02399

Conclusion of examination: Maintain patent No. 97180299.8 on the basis of the claim filed by the patent holder in April 7, 2009.

Decision date of declaring invalidation: 20090422

Decision number of declaring invalidation: 13179

Denomination of invention: Subsitutted 2(2,6-dioxopiperidin-3-yl) phthalimides and -1-xoisoindolines and method of reducing TNF-alpha levels

Granted publication date: 20030806

Patentee: Celgene Corp.

IW01 Full invalidation of patent right
IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20131128

Decision number of declaring invalidation: 21646

Granted publication date: 20030806